Phase 2 evaluation of rozanolixizumab for moderate-to-severe generalized myasthenia gravis


  • While rozanolixizumab did not meet the primary endpoint of significant improvement in Quantitative Myasthenia Gravis (QMG) score at day 29, results of all pre-specified efficacy measures (QMG, MG-Activities of Daily Living [MG-ADL] and MG-Composite [MGC]) indicate that rozanolixizumab may provide clinical benefit for patients with moderate-to-severe generalized myasthenia gravis (gMG).

Why this matters

    Rozanolixizumab has shown dose-dependent reductions in immunoglobulin G (IgG) concentrations in healthy volunteers; its efficacy and safety in phase 2 studies of gMG will determine whether it is a viable treatment option for further consideration.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.